
Biotech firm, Lux Biosciences, innovates and commercializes treatments for severe ophthalmic diseases in the US.
Lux Biosciences, founded to address unmet needs in ophthalmic care, is a clinical-stage biotechnology company focused on developing and commercializing medications for serious eye diseases. The company's core mission is to improve the quality of life for patients suffering from severe ophthalmic conditions through innovative treatments. Lux Biosciences primarily serves the United States market, targeting both patients and healthcare providers with its specialized therapeutic solutions.
Notable affiliated individuals and investors in Lux Biosciences include key figures from the biotechnology and pharmaceutical sectors, although specific names are not provided. The company has achieved significant milestones in advancing its clinical trials and securing regulatory approvals for its products. Lux Biosciences' impact is evident in its commitment to addressing critical gaps in ophthalmic care, contributing to the overall advancement of medical treatments for eye diseases.

Visiox
visioxpharma.com

Qlaris Bio
qlaris.bio

Aurion Biotech
aurionbiotech.com

Ocular Science
ocularscience.com

Imagen Biotech

Lumen Bioscience

EyeCyte
eyecyte.com

Lenticular Research Group

Brii Biosciences
briibio.com

Harmony Biosciences

Lumos Pharma
lumos-pharma.com

Surface Pharmaceuticals
surfacepharma.com

Ocular Therapeutix
ocutx.com

Superior Biologics

LumiThera
lumithera.com
Companies similar to Lux Biosciences include Visiox, Qlaris Bio, Aurion Biotech and Ocular Science.
Lux Biosciences was founded in 2005.
Lux Biosciences' headquarters is located in Jersey City, NJ, US.
Lux Biosciences' most recent funding round was for $16M (USD) in March 2012.
As of Mar 6, 2012, Lux Biosciences has raised a total of $129.2M (USD).